| Literature DB >> 30722792 |
Kyungmin Lee1, Jangwook Lee1, Minjeong Kwak2, Young-Lai Cho3, Byungtae Hwang1, Min Ji Cho1,4, Na Geum Lee1,4, Jongjin Park1,4, Sang-Hyun Lee1, Jong-Gil Park1, Yeon-Gu Kim1, Jang-Seong Kim1, Tae-Su Han1, Hyun-Soo Cho5, Young-Jun Park3, Seon-Jin Lee6, Hee Gu Lee6, Won Kon Kim3, In Cheul Jeung7, Nam Woong Song8, Kwang-Hee Bae9, Jeong-Ki Min10,11.
Abstract
BACKGROUND: Silica nanoparticles (SiNPs) are widely used for biosensing and diagnostics, and for the targeted delivery of therapeutic agents. Safety concerns about the biomedical and clinical applications of SiNPs have been raised, necessitating analysis of the effects of their intrinsic properties, such as sizes, shapes, and surface physicochemical characteristics, on human health to minimize risk in biomedical applications. In particular, SiNP size-associated toxicological effects, and the underlying molecular mechanisms in the vascular endothelium remain unclear. This study aimed to elucidate the detailed mechanisms underlying the cellular response to exposure to trace amounts of SiNPs and to determine applicable size criteria for biomedical application.Entities:
Keywords: Apoptosis; Autophagy; Necroptosis; ROS; Silica nanoparticles
Mesh:
Substances:
Year: 2019 PMID: 30722792 PMCID: PMC6362579 DOI: 10.1186/s12951-019-0456-4
Source DB: PubMed Journal: J Nanobiotechnology ISSN: 1477-3155 Impact factor: 10.435
Fig. 1Characteristics and size-dependent cytotoxicity of silica nanoparticles (SiNPs). a TEM images of 20-nm and 50-nm SiNPs showing that both SiNPs were spherical and displayed monodispersity. b Analysis of DLS data from aqueous suspensions of SiNPs with different sizes ([SiNP] = 1 mg/mL). The size distribution was 18.7 ± 8.4, 30.2 ± 14.2, 37.8 ± 15.0, and 50.4 ± 21.1 nm. Size-dependent cytotoxicity of SiNPs in Human umbilical vein ECs (HUVECs). c Assessment of endothelial cell (EC) viability following treatment with different sizes of SiNPs. Human umbilical vein ECs (HUVECs) were treated with the indicated concentrations of the SiNPs for 24 h in low serum-containing condition and analyzed using crystal violet assay. d Morphologies of HUVECs following treatment with 20 μg/mL SiNPs for 24 h were showed using an optical microscopy, and e representative bar graph of the percentages of apoptotic and necrotic cells as determined by flow cytometric analysis (early apoptotic cell: annexin-V(+)/PI (−), late apoptotic cell: annexin-V(+)/PI (+), and necrotic cell: annexin-V(−)/PI (+); **p < 0.01 versus 30–50-nm SiNPs treated HUVECs). f Relative caspase 3/7 activity of HUVECs treated with 20 μg/mL SiNPs was quantified by Caspase-Glo 3/7 assay systems (**p < 0.01 versus 30–50-nm SiNPs treated HUVECs). Quantitative data are reported as means ± standard deviations. *p < 0.005 versus 30–50-nm SiNPs treated HUVECs. g Western blot analysis of caspase-3 activation in HUVECs following treatment with SiNPs for 24 h. h Interaction between RIPK1–RIPK3 was detected by immunoprecipitation (IP) and western blot analysis
Fig. 2ROS/ER stress attenuated 20-nm SiNP-induced apoptosis cell death in HUVECs. a Western blot analysis of expression of Binding immunoglobulin Protein (BiP) and inositol-requiring kinase-1α (IRE1α) in HUVECs following treatment with different sizes of SiNPs for 24 h in low serum-containing condition. Effect of ER stress on SiNPs-induced apoptotic or necrotic cell death. HUVECs were transfected with IRE1α-targeted or control siRNA and subsequently treated with 20-nm SiNP for 24 h. b Dose-dependent cell viability, c relative caspase-3/7 activity, and d, e western blot analysis of caspase-3 activation and immunoprecipitation between RIPK1–RIPK3 in control or IRE1α siRNA-transfected HUVECs with SiNPs at 20 μg/mL for 24 h. Effect of an intracellular ROS inhibitors on SiNPs-induced ER stress in HUVECs. f Relative ROS level in HUVECs treated with the indicated sizes and concentration of SiNPs for 24 h. g Western blot analysis of expression of BiP and IRE1α in HUVECs were pretreated with 10 μM of Apocynin and Mito-Tempo for 30 min and subsequently treated with 20-nm SiNP for 5 h
Fig. 3Induction of autophagy in 20-nm SiNP treated HUVECs. a–d Western blot analysis of microtubule-associated protein 1B-light chain 3 (LC3B)-I to LC3B-II conversion in HUVECs treated with the indicated sizes and concentration of SiNPs for 24 h in low serum-containing condition, and it also tested time-dependent analysis. Relative LC3-II to LC3-I ratios are indicated in the graph. Data were quantified using Image J software. e Representative images of green fluorescent protein (GFP)–LC3 punctae in HUVECs after treatment with SiNPs at 20 μg/mL for 12 h. Bar graph indicates the number of GFP–LC3 dots per transfected cells. Quantitative data are reported as means ± standard deviations. **p < 0.01 versus 30–50 nm SiNPs treated HUVECs. f Turnover assays for LC3 to determine the overall autophagic flux in HUVECs treated with 10 nM Bafilomycin A1 (lysosomal inhibitor) for 30 min and subsequently treated with 20-nm SiNP for 5 h. LC3-I to LC3-II conversion was detected by Western blot analysis
Fig. 420-nm SiNP-induced autophagy depends on PI3K/AKT/eNOS/nitric oxide signaling pathway. a Western blot analysis of LC3B-I to LC3B-II conversion in HUVECs treated with 10 μM of Apocynin and Mito-Tempo for 30 min and subsequently treated with 20-nm SiNPs at 20 μg/mL for 5 h. Relative LC3-II to LC3-I ratios are indicated in the graph using Image J software. SiNPs-induced autophagy depends on PI3K/AKT or eNOS signaling pathway activation, but independent of ROS or AMPK. b Western blot analysis of LC3B-I to LC3B-II conversion and and AKT, AMP-activated protein kinase (AMPK), endothelial NO-synthase (eNOS), and p38 phosphorylation. HUVECs were treated with 20- and 50-nm of SiNPs for the indicated times at 20 μg/mL. c, d Western blot analysis of LC3-I to LC3-II conversion and AMPK phosphorylation or p38 phosphorylation in HUVECs treated with indicated concentrations of Compound-C and SB203580 for 30 min and subsequently treated with 20-nm SiNPs at 20 μg/mL for 5 h, respectively. e–g Western blot analysis of the LC3-I to LC3-II conversion following treatment with PI3K inhibitor (Wortmannin), eNOS inhibitor (L-LAME), and eNOS siRNA, respectively. Relative LC3-II to LC3-I ratios are quantified by Image J software
Fig. 5Induction of autophagy attenuated 20-nm SiNP-induced necrotic cell death in HUVECs. HUVECs were transfected with LC3B-targeted or control siRNA and subsequently treated with the indicated concentrations of the 20-nm SiNP for 24 h in low serum-containing condition. a Dose-dependent cell viability was determined using the crystal violet assay. b Representative bar graph of the percentages of apoptotic and necrotic cells was quantified by flow cytometric analysis. c, d Western blot analysis of immunoprecipitation between RIPK1–RIPK3 and caspase-3 activation in the transfected cells. e, f Western blot analysis of the BiP, IRE1α, and LC3-I to LC3-II conversion in HUVECs were transfected with LC3B or IRE1α siRNA and subsequently treated with the indicated concentrations of the 20-nm SiNP for 24 h in low serum-containing condition
Fig. 6Overview of SiNPs-induced apoptotic and necrotic cell death pathways independently in HUVECs. The 20-nm SiNP exposed to the membrane of endothelial cells, leading to intracellular ROS level. NADPH oxidase (NOX), a non-mitochondrial source of ROS increase, generates superoxide anions through oxygen reduction mediated by the electron donor NADPH. NOX-derived ROS contribute ER stress and activate unfolded protein response (UPR), resulting that IRE1α dissociated from BiP responses the unfolded proteins. Subsequently, the resultant trans-autophosphorylation induce apoptotic cell death. In addition, 20-nm SiNP induce autophagy activation, independent of ROS, via PI3K/AKT/eNOS/nitric oxide signaling pathway. Under the induction of autophagy, RIP1 interacts with RIP3 to form complex Iib, which is involved in necroptosis. As a result, autophagy induced by 20-nm SiNP causes necrotic cell death